Evgen, a Liverpool, UK-based company that develops a new cancer treatment, has raised £460k in funding.
Led by CEO Dr Stephen Franklin, Evgen is developing Sulforadex, a synthetic pharmaceutical based on sulforaphane, a substance produced in the body after eating broccoli and other vegetables in the cabbage family, whose cancer protective benefits have been well documented.
The company, which has also attracted a £225k grant from the UK Government-backed Technology Strategy Board, intends to use the funding to begin clinical trials on its key product Sulforadex, which has potential applications across multiple cancers. In the first instance, the company is developing Sulforadex for use in early stage “indolent” prostate cancer.
20/09/2011: Evgen Raises Series A Funding